EpiTherapeutics ApS - ChemAxon€¦ · Director of Drug Discovery . 2 Agenda Brief company overview...
Transcript of EpiTherapeutics ApS - ChemAxon€¦ · Director of Drug Discovery . 2 Agenda Brief company overview...
![Page 1: EpiTherapeutics ApS - ChemAxon€¦ · Director of Drug Discovery . 2 Agenda Brief company overview Use of IJC as an integrated tool in our Discovery Process Further Development.](https://reader033.fdocuments.us/reader033/viewer/2022043023/5f3f28f254910a643b08f6cc/html5/thumbnails/1.jpg)
EpiTherapeutics ApS Integrating Instant Jchem in the Discovering Organization of a Biopharmaceutical Startup ChemAxon UGM, Budapest May 2012 Thomas Boesen, PhD Director of Drug Discovery
![Page 2: EpiTherapeutics ApS - ChemAxon€¦ · Director of Drug Discovery . 2 Agenda Brief company overview Use of IJC as an integrated tool in our Discovery Process Further Development.](https://reader033.fdocuments.us/reader033/viewer/2022043023/5f3f28f254910a643b08f6cc/html5/thumbnails/2.jpg)
2
Agenda
Brief company overview
Use of IJC as an integrated tool in our Discovery Process
Further Development
![Page 3: EpiTherapeutics ApS - ChemAxon€¦ · Director of Drug Discovery . 2 Agenda Brief company overview Use of IJC as an integrated tool in our Discovery Process Further Development.](https://reader033.fdocuments.us/reader033/viewer/2022043023/5f3f28f254910a643b08f6cc/html5/thumbnails/3.jpg)
3
• Founded October 2008 on seminal research by world-leaders in oncology and epigenetics, Professor Kristian Helin and colleagues of BRIC, Copenhagen. Exclusive collaboration agreement with BRIC and right of first refusal to new IP from BRIC
Executive Summary
• $ 9.1 mill seed investment by Seed Capital, Novo Seeds, Lundbeckfond Ventures, Astellas Ventures and Merck Serono Ventures
• 3-year research collaboration agreement signed with Abbott December 2010
• Key targets are histone demethylases and histone methyltransferases with the potential for creating truly innovative cancer treatments
• Most progressed program (GASC1) is in early lead optimization with several compounds in the single digit nM range and inhibition of cellular GASC1 activity. Good PK data
• Preparing for Series A financing of USD 25M and seeking pharma partnerships to apply insight within epigenetic tumor biology
• 17 employees in Copenhagen/New Jersey (14 PhDs), 8 FTEs in Canada (PhDs)
![Page 4: EpiTherapeutics ApS - ChemAxon€¦ · Director of Drug Discovery . 2 Agenda Brief company overview Use of IJC as an integrated tool in our Discovery Process Further Development.](https://reader033.fdocuments.us/reader033/viewer/2022043023/5f3f28f254910a643b08f6cc/html5/thumbnails/4.jpg)
4
EpiTherapeutics focuses on two epigenetic enzyme families
DNA Methylation
• CpG Methylation/Demethylation?
Histone Modifications
• Acetylation/Deacetylation of Histones • Methylation/Demethylation of Histones
• Other Modifications of Histones
5’ 5’
3’ 3’
Deoxycytidine 5-Methyl-cytidine
DNMT
DNDM?
e-N-Methyl-Lysine
e-N-Acetyl-Lysine Lysine
Lysine
KAT
KDM
HDAC
KMT
The focus of EpiTherapeutics
![Page 5: EpiTherapeutics ApS - ChemAxon€¦ · Director of Drug Discovery . 2 Agenda Brief company overview Use of IJC as an integrated tool in our Discovery Process Further Development.](https://reader033.fdocuments.us/reader033/viewer/2022043023/5f3f28f254910a643b08f6cc/html5/thumbnails/5.jpg)
5
GASC1 Summary
Cancer GASC1
amplification
Excess H3K9 demethylation
Androgen receptor
activation
Expression of oncogenes
GASC1 inhibitors
Genomic instability
Overriding senescence
5
![Page 6: EpiTherapeutics ApS - ChemAxon€¦ · Director of Drug Discovery . 2 Agenda Brief company overview Use of IJC as an integrated tool in our Discovery Process Further Development.](https://reader033.fdocuments.us/reader033/viewer/2022043023/5f3f28f254910a643b08f6cc/html5/thumbnails/6.jpg)
6
Current activities include programs targeting both HDMs and HMTs
Pipeline – status of current internal projects
• GASC1 (HDM)
Assay Development HTS Hit-to-Lead Lead Optimization
• PLU1 (HDM)
Status of current collaborations
• X, Y, Z… Details from collaboration have not been disclosed
• DOT1L (HMT)
Assay Development HTS
![Page 7: EpiTherapeutics ApS - ChemAxon€¦ · Director of Drug Discovery . 2 Agenda Brief company overview Use of IJC as an integrated tool in our Discovery Process Further Development.](https://reader033.fdocuments.us/reader033/viewer/2022043023/5f3f28f254910a643b08f6cc/html5/thumbnails/7.jpg)
7
Agenda
Brief company overview
Use of IJC as an integrated tool in our Discovery Process
Further Development
![Page 8: EpiTherapeutics ApS - ChemAxon€¦ · Director of Drug Discovery . 2 Agenda Brief company overview Use of IJC as an integrated tool in our Discovery Process Further Development.](https://reader033.fdocuments.us/reader033/viewer/2022043023/5f3f28f254910a643b08f6cc/html5/thumbnails/8.jpg)
8
What we do
SAR: Structure Activity Relationship
Compound Design
Compound Synthesis /Purchase
Compound Testing
![Page 9: EpiTherapeutics ApS - ChemAxon€¦ · Director of Drug Discovery . 2 Agenda Brief company overview Use of IJC as an integrated tool in our Discovery Process Further Development.](https://reader033.fdocuments.us/reader033/viewer/2022043023/5f3f28f254910a643b08f6cc/html5/thumbnails/9.jpg)
9
How we are organized
Cpd characterization Screening
Target validation In vitro biology
Other CROs • ADME • PK • Compound characterization DATA • Protocols • Test results
Project Leadership Project Management
8 FTEs (Ph.D.)
Chemistry CRO • Synthesize compounds for
testing DATA • Compound identity and
structure • Analytical data • Amounts • Procedures and notebooks
Chemical vendors DATA • Compound identity and
structure • Analytical data • Amounts
Internal laboratories • Screening • Functional cell assays • Target validation DATA • Protocols • Test results
The database becomes the “common language” of chemist and biologists
![Page 10: EpiTherapeutics ApS - ChemAxon€¦ · Director of Drug Discovery . 2 Agenda Brief company overview Use of IJC as an integrated tool in our Discovery Process Further Development.](https://reader033.fdocuments.us/reader033/viewer/2022043023/5f3f28f254910a643b08f6cc/html5/thumbnails/10.jpg)
Software specifications
10
• Ease of use • No in-house programming
expertise • Users with different
background
• Compatible
• OS • Third party software
• Scalable
• Reliable/proven
• Versatile • Innovative organization
Database
End User interface
![Page 11: EpiTherapeutics ApS - ChemAxon€¦ · Director of Drug Discovery . 2 Agenda Brief company overview Use of IJC as an integrated tool in our Discovery Process Further Development.](https://reader033.fdocuments.us/reader033/viewer/2022043023/5f3f28f254910a643b08f6cc/html5/thumbnails/11.jpg)
Design of Database Specifications
11
• Traceability • Integrated with our data management setup • Compound batch and experiment level
• Versatile
• Types of data • A variety of assays and experiments
• Security
• User level • Project level
• Primary Key
• Compound Number
• Tool to enable SAR
![Page 12: EpiTherapeutics ApS - ChemAxon€¦ · Director of Drug Discovery . 2 Agenda Brief company overview Use of IJC as an integrated tool in our Discovery Process Further Development.](https://reader033.fdocuments.us/reader033/viewer/2022043023/5f3f28f254910a643b08f6cc/html5/thumbnails/12.jpg)
Basic Tables
12
Pivot – SAR table
Structure •Unique structure for
each EPT number
Project •User level security
/access
Secondary Assays •Dose response
screening
Primary Assays •Single point
screening
Batch
![Page 13: EpiTherapeutics ApS - ChemAxon€¦ · Director of Drug Discovery . 2 Agenda Brief company overview Use of IJC as an integrated tool in our Discovery Process Further Development.](https://reader033.fdocuments.us/reader033/viewer/2022043023/5f3f28f254910a643b08f6cc/html5/thumbnails/13.jpg)
Batch table
13
![Page 14: EpiTherapeutics ApS - ChemAxon€¦ · Director of Drug Discovery . 2 Agenda Brief company overview Use of IJC as an integrated tool in our Discovery Process Further Development.](https://reader033.fdocuments.us/reader033/viewer/2022043023/5f3f28f254910a643b08f6cc/html5/thumbnails/14.jpg)
Secondary Assays Table
14
Structure removed
![Page 15: EpiTherapeutics ApS - ChemAxon€¦ · Director of Drug Discovery . 2 Agenda Brief company overview Use of IJC as an integrated tool in our Discovery Process Further Development.](https://reader033.fdocuments.us/reader033/viewer/2022043023/5f3f28f254910a643b08f6cc/html5/thumbnails/15.jpg)
SAR Table
15
Structure removed
![Page 16: EpiTherapeutics ApS - ChemAxon€¦ · Director of Drug Discovery . 2 Agenda Brief company overview Use of IJC as an integrated tool in our Discovery Process Further Development.](https://reader033.fdocuments.us/reader033/viewer/2022043023/5f3f28f254910a643b08f6cc/html5/thumbnails/16.jpg)
What it takes to maintain the database
16
User level
• Scientists easily upload data • Data can easily be QC’ed • Data is easily accessed by Scientists
Administrator level
• Pivoting requires MySql programming • Time consuming • Complex • Performance
![Page 17: EpiTherapeutics ApS - ChemAxon€¦ · Director of Drug Discovery . 2 Agenda Brief company overview Use of IJC as an integrated tool in our Discovery Process Further Development.](https://reader033.fdocuments.us/reader033/viewer/2022043023/5f3f28f254910a643b08f6cc/html5/thumbnails/17.jpg)
Agenda
Brief company overview
Use of IJC as an integrated tool in our Discovery Process
Further Development
![Page 18: EpiTherapeutics ApS - ChemAxon€¦ · Director of Drug Discovery . 2 Agenda Brief company overview Use of IJC as an integrated tool in our Discovery Process Further Development.](https://reader033.fdocuments.us/reader033/viewer/2022043023/5f3f28f254910a643b08f6cc/html5/thumbnails/18.jpg)
Further Possible Development of our IJC setup
18
Data Reporting
• Graphs • Correlations
• Build in Functions
Exporting options
• Overviews on slides (SAR) or in documents
![Page 19: EpiTherapeutics ApS - ChemAxon€¦ · Director of Drug Discovery . 2 Agenda Brief company overview Use of IJC as an integrated tool in our Discovery Process Further Development.](https://reader033.fdocuments.us/reader033/viewer/2022043023/5f3f28f254910a643b08f6cc/html5/thumbnails/19.jpg)
Thank you for your attention!